Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
NCT ID: NCT03789006
Last Updated: 2019-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
300 participants
INTERVENTIONAL
2018-03-21
2024-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
NCT01780844
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
NCT02723786
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
NCT00724022
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
NCT00113269
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
NCT03994783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATG
Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
Antithymocyte Immunoglobulin (Rabbit)
Induction agent for living donor kidney transplantation
BAS
Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
Interleukin 2 Receptor Antagonist
Induction agent for living donor kidney transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antithymocyte Immunoglobulin (Rabbit)
Induction agent for living donor kidney transplantation
Interleukin 2 Receptor Antagonist
Induction agent for living donor kidney transplantation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First living donor kidney transplant.
* Moderate immunological risk.
Exclusion Criteria
* High immunological risk (child to mother or husband to wife transplant, 2 DR mismatches).
* Known hypersensitivity to any of the study medication.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Kidney Diseases and Surgery
UNKNOWN
University of Khartoum
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarra Elamin
Consultant Physician and Nephrologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarra Elamin, MD
Role: PRINCIPAL_INVESTIGATOR
Consultant Nephrologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Doctor Salma Center for Kidney Diseases
Khartoum, , Sudan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
033546
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.